Cargando…
Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
Patients with advanced non-small cell lung cancer receive first-line therapy with chemotherapy, targeted therapies in case of tumors with driver mutations, and more recently also immune checkpoint inhibitors. Important controversies include the role of targeted therapies in combination with chemothe...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Vienna
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006273/ https://www.ncbi.nlm.nih.gov/pubmed/29983826 http://dx.doi.org/10.1007/s12254-018-0408-y |